Post-Spinal ShiveringPhase 4OOPSNCT07088601
Efficacy of Oral Ondansetron Strips on Prevention of Post-Spinal Shivering
A Phase 4 study testing Oral ondansetron strips in people with Post-Spinal Shivering, run by Cairo University.
Trial summary
This study aims to investigate the efficacy of oral ondansetron film strips on the incidence of post-spinal shivering in patients undergoing surgeries using spinal anesthesia at Kasr Alainy hospitals, Cairo University. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Post-Spinal Shivering
- What is being tested?
- Oral ondansetron strips
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 10 Aug 2025to 29 Dec 2025
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- American Society of Anesthesiologists (ASA) physical status I, II.
- Patients underwent elective surgical procedures under spinal anesthesia in the lower half of the body such as orthopedic, urological, or general surgeries.
Who cannot join
- Patient refusal.
- Morbid obese patients or those who were not candidates for spinal anesthesia.
- Pregnant females.
- Patients with comorbidities such as severe cardiopulmonary, severe hepatic or renal diseases, thyroid disorders, and convulsions.
- Uncooperative patients and patients with psychological disorders.
- Patients on regular ondansetron or other antiemetics.
Show all 10Show fewer
- Patients taking selective serotonin reuptake inhibitors.
- Patients with allergy to 5-HT3 receptor antagonist drugs.
- Patients receiving saddle spinal block.
- In surgeries less than 1 h or longer than 3 hours duration.
About this study
Official title: Efficacy of Oral Ondansetron Strips on Prevention of Post-Spinal Shivering; a Double Blinded, Randomized Controlled Study
This study aims to investigate the efficacy of oral ondansetron film strips on the incidence of post-spinal shivering in patients undergoing surgeries using spinal anesthesia at Kasr Alainy hospitals, Cairo University.
This prospective, double-blinded, randomized controlled study will be conducted on 50 patients aged from 18 to 65 years of both sexes with ASA I, II who are scheduled for elective surgical procedures under spinal anesthesia in the lower half of the body such as orthopedic, urological, or general surgeries. Patients will be divided into two equal groups: Group (O) will receive oral ondansetron in the form of an oral soluble film 4 mg strip immediately before insertion of IV cannula and group (C) will receive a placebo in the form of an oral peppermint strip immediately before insertion of the IV cannula.
Read the detailed description
In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip (Ondalenz, 4 mg orodispersible films of Nerhadou International Co.) and patients in group C will receive a placebo in the form of an oral peppermint strip (Listerine Cool Mint Pocketpakas).
Following the insertion of a cannula; IV midazolam at a dose of 0.05 mg/kg will be administered intravenously. Then the patient will be transferred immediately to the operating theatre.
On entering the operating room; all patients will be connected to standard ASA monitoring which included electrocardiography (ECG), non-invasive arterial blood pressure (NIBP) including systolic, diastolic, mean arterial blood pressure (MAP) and Oxygen saturation using pulse oximetry.
With the patient sitting on the operating table, the L3-L4 interspace will be identified by identification of Tuffier's line. Under complete aseptic conditions, a dural puncture will be achieved by a 22G pencil-point spinal needle that will be introduced in a paramedian (lateral) approach through the L3-4 intervertebral space. After CSF aspiration and confirmation of correct intrathecal space, 3.5 mL of Sunny Pivacaine 0.5% (hyperbaric bupivacaine 20mg/4mL amp of Sunny pharmaceutical group) plus 25 μg of fentanyl-Hameln (of Sunny pharmaceutical group) will be injected over one minute.
The sensory block will be assessed by a pinprick test and the motor block will be assessed using a modified Bromage scale (0 = no motor block; 1= hip is blocked; 2= hip and knee are blocked; 3= hip, knee, and ankle are blocked). Peak sensory level will be confirmed and if a sensory level < T8 the patient will be excluded. If general anesthesia is needed for any reason, the patient will also be excluded from the study.
The ambient room temperature will be maintained at 24°C. IV fluids will be administered according to the conventional way as follows, hourly maintenance was the sum of A (4x first 10 Kg body weight), B (2x next 10 Kg body weight) and C (1x remaining Kg bodyweight) in addition to deficit (or fasting requirements), that will be hourly maintenance multiplied by the numbers of hours of fasting, half of it will be administered in the first hour and the second half will bne administered during second and third hours of surgery. Balanced crystalloids such as Ringer's lactate or acetate will be preferred over normal saline. Blood loss will be estimated through the surgical field, towels, gauzes and suction jar \& will be replaced by crystalloids 1:3 or colloid/blood and blood products 1:1 ratio. All IV fluids will be administered at room temperature. All patients will be covered with surgical drapes from the lower extremities up to the lower chest during the operation. No warming devices will be used. Supplementary oxygen by a face mask will be given to all patients at a rate of 6 L/min.
The tympanic temperature will be monitored and measured by using the Braun ThermoScan 5 Ear Thermometer model IRT 6500. Hypothermia will be defined as a tympanic membrane temperature < 36.5◦ C.
Shivering score will then be assessed according to the Bedside shivering assessment score (BSAS) . If shivering scores ≥ 3, 30 mg of IV pethidine were administered as a rescue dose.
Postoperative:
Patients will be discharged to post anesthesia care unit (PACU). All patients will be monitored in the post-anesthesia care unit (PACU), covered by one cotton blanket over their entire body. The PACU temperature will be maintained at 24ºC.
The adverse effects will be assessed: allergic reaction from the used drugs, complications from the surgery done as:
Hypotension (MAP < 20% of baseline). In case of hypotension, the patients will be managed with intravenous loading with Ringer's lactate and boluses of 10 mg ephedrine IV.
Bradycardia (HR< 60 beats/min). In the case of bradycardia, the patients will be managed with 0.02 mg/kg atropine IV.
Respiratory depression will be considered if the respiratory rate is less than 10 breaths per minute and oxygen saturation (SpO2) was < 92% for 30 or more seconds.
- Conditions
- Post-Spinal Shivering
- Being tested
- Oral ondansetron strips, Placebo (oral peppermint strip)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral ondansetron stripsDrug
In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip.
Placebo (oral peppermint strip)Other
In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group C will receive a placebo in the form of an oral peppermint strip.
| Study group | Role | What they receive |
|---|---|---|
| Group O | Active comparator | Patients will receive oral ondansetron in the form of an oral soluble film 4 mg strip. Receives: Drug: Oral ondansetron strips |
| Group C | Placebo comparator | Patients will receive a placebo in the form of an oral peppermint strip Receives: Other: Placebo (oral peppermint strip) |
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence of shivering.
It is defined by the highest shivering score ≥ 3 at any time starting from 15 min after lumber puncture until 180 min following it.
Measured: starting from 15 minutes after lumber puncture until 180 minutes following it and postoperative.
Secondary outcomes (7)
The onset time of significant shivering
Time in min from the onset of significant shivering ≥ 3 on shivering score
Measured: started from 15 minutes after lumbar injection until 180 minutes following lumbar injection and postoperative
Incidence of hypothermia
Core body temperature will be measured by ear thermometer immediately before lumbar puncture (base level), and then at 15-minute intervals until 180 min after lumbar puncture and postoperative. Hypothermia will be defined as a tympanic membrane temperature < 36.5◦ C.
Measured: started from 15 minutes after lumbar injection until 180 minutes after lumbar injection and postoperative.
The shivering score
Shivering score will be assessed according to the Bedside shivering assessment score (BSAS) as: Grade I: Mild fasciculation of face, neck, or head, or peripheral vasoconstriction, Grade II: Visible tremor involving one muscle group, Grade III Muscular activity in more than one muscle group but not generalized, and Grade IV: Gross muscular activity involving the entire body. The minimum is grade I and the maximum is Grade IV. Higher grades mean increased severity.
Measured: will be assessed at 15 minutes intervals during the operation and in the recovery room started from 15 minutes after the lumbar puncture until 180 minutes after the lumbar puncture and postoperative.
Incidence of patients given pethidine
If shivering scores ≥ 3, 30 mg of IV pethidine will be administered as a rescue dose.
Measured: started from 15 minutes after the lumbar puncture until 180 minutes after the lumbar puncture and postoperativde.
Correlation between the incidence of shivering score ≥ 3 and hypothermia.
Correlation between the incidence of shivering score ≥ 3 as measured by Bedside Shivering Assessment Score (BSAS) and hypothermia as measured by tympanic thermometer (<36.5).
Measured: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively
The incidence of adverse effects
e.g., hypotension, arrhythmias as bradycardia, nausea, vomiting, headache, itching, hypoxemia, and total spinal block) will be detected and recorded
Measured: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively
Correlation between the incidences of postoperative nausea, vomiting, and shivering
Measured: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2025
- Study start10 Aug 2025 (estimated)
- Primary completion29 Dec 2025 (estimated)
- Study completion29 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Post-Spinal ShiveringStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hany Mohammed El-Hadi Shoukat Mohammed, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07088601
- Sponsor's protocol ID
- MS-442-2024
- Acronym
- OOPS
- Status last verified
- Dec 2024
- First submitted
- 19 Jul 2025
- Last updated
- 30 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Oral Ondansetron Strips on Prevention of Post-Spinal Shivering; a Double Blinded, Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT07088601
- Acronym / sponsor ID
- OOPS / MS-442-2024
- Conditions
- Post-Spinal Shivering
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 10 Aug 2025 (estimated)
- Primary completion
- 29 Dec 2025 (estimated)
- Study completion
- 29 Dec 2025 (estimated)
- First posted
- 28 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the efficacy of oral ondansetron film strips on the incidence of post-spinal shivering in patients undergoing surgeries using spinal anesthesia at Kasr Alainy hospitals, Cairo University.
This prospective, double-blinded, randomized controlled study will be conducted on 50 patients aged from 18 to 65 years of both sexes with ASA I, II who are scheduled for elective surgical procedures under spinal anesthesia in the lower half of the body such as orthopedic, urological, or general surgeries. Patients will be divided into two equal groups: Group (O) will receive oral ondansetron in the form of an oral soluble film 4 mg strip immediately before insertion of IV cannula and group (C) will receive a placebo in the form of an oral peppermint strip immediately before insertion of the IV cannula.
Detailed description
In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip (Ondalenz, 4 mg orodispersible films of Nerhadou International Co.) and patients in group C will receive a placebo in the form of an oral peppermint strip (Listerine Cool Mint Pocketpakas).
Following the insertion of a cannula; IV midazolam at a dose of 0.05 mg/kg will be administered intravenously. Then the patient will be transferred immediately to the operating theatre.
On entering the operating room; all patients will be connected to standard ASA monitoring which included electrocardiography (ECG), non-invasive arterial blood pressure (NIBP) including systolic, diastolic, mean arterial blood pressure (MAP) and Oxygen saturation using pulse oximetry.
With the patient sitting on the operating table, the L3-L4 interspace will be identified by identification of Tuffier's line. Under complete aseptic conditions, a dural puncture will be achieved by a 22G pencil-point spinal needle that will be introduced in a paramedian (lateral) approach through the L3-4 intervertebral space. After CSF aspiration and confirmation of correct intrathecal space, 3.5 mL of Sunny Pivacaine 0.5% (hyperbaric bupivacaine 20mg/4mL amp of Sunny pharmaceutical group) plus 25 μg of fentanyl-Hameln (of Sunny pharmaceutical group) will be injected over one minute.
The sensory block will be assessed by a pinprick test and the motor block will be assessed using a modified Bromage scale (0 = no motor block; 1= hip is blocked; 2= hip and knee are blocked; 3= hip, knee, and ankle are blocked). Peak sensory level will be confirmed and if a sensory level < T8 the patient will be excluded. If general anesthesia is needed for any reason, the patient will also be excluded from the study.
The ambient room temperature will be maintained at 24°C. IV fluids will be administered according to the conventional way as follows, hourly maintenance was the sum of A (4x first 10 Kg body weight), B (2x next 10 Kg body weight) and C (1x remaining Kg bodyweight) in addition to deficit (or fasting requirements), that will be hourly maintenance multiplied by the numbers of hours of fasting, half of it will be administered in the first hour and the second half will bne administered during second and third hours of surgery. Balanced crystalloids such as Ringer's lactate or acetate will be preferred over normal saline. Blood loss will be estimated through the surgical field, towels, gauzes and suction jar \& will be replaced by crystalloids 1:3 or colloid/blood and blood products 1:1 ratio. All IV fluids will be administered at room temperature. All patients will be covered with surgical drapes from the lower extremities up to the lower chest during the operation. No warming devices will be used. Supplementary oxygen by a face mask will be given to all patients at a rate of 6 L/min.
The tympanic temperature will be monitored and measured by using the Braun ThermoScan 5 Ear Thermometer model IRT 6500. Hypothermia will be defined as a tympanic membrane temperature < 36.5◦ C.
Shivering score will then be assessed according to the Bedside shivering assessment score (BSAS) . If shivering scores ≥ 3, 30 mg of IV pethidine were administered as a rescue dose.
Postoperative:
Patients will be discharged to post anesthesia care unit (PACU). All patients will be monitored in the post-anesthesia care unit (PACU), covered by one cotton blanket over their entire body. The PACU temperature will be maintained at 24ºC.
The adverse effects will be assessed: allergic reaction from the used drugs, complications from the surgery done as:
Hypotension (MAP < 20% of baseline). In case of hypotension, the patients will be managed with intravenous loading with Ringer's lactate and boluses of 10 mg ephedrine IV.
Bradycardia (HR< 60 beats/min). In the case of bradycardia, the patients will be managed with 0.02 mg/kg atropine IV.
Respiratory depression will be considered if the respiratory rate is less than 10 breaths per minute and oxygen saturation (SpO2) was < 92% for 30 or more seconds.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group O | Active comparator | Drug: Oral ondansetron stripsPatients will receive oral ondansetron in the form of an oral soluble film 4 mg strip. |
| Group C | Placebo comparator | Other: Placebo (oral peppermint strip)Patients will receive a placebo in the form of an oral peppermint strip |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- American Society of Anesthesiologists (ASA) physical status I, II.
- Patients underwent elective surgical procedures under spinal anesthesia in the lower half of the body such as orthopedic, urological, or general surgeries.
Key exclusion criteria (10 listed)
- Patient refusal.
- Morbid obese patients or those who were not candidates for spinal anesthesia.
- Pregnant females.
- Patients with comorbidities such as severe cardiopulmonary, severe hepatic or renal diseases, thyroid disorders, and convulsions.
- Uncooperative patients and patients with psychological disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral ondansetron stripsIn the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group O will receive oral ondansetron in the form of an oral soluble film 4 mg strip. | Drug | Group O |
| Placebo (oral peppermint strip)In the anesthesia preparation room and before the insertion of the peripheral IV cannula, patients in group C will receive a placebo in the form of an oral peppermint strip. | Other | Group C |
Primary outcome
The incidence of shivering.
Time frame: starting from 15 minutes after lumber puncture until 180 minutes following it and postoperative.
It is defined by the highest shivering score ≥ 3 at any time starting from 15 min after lumber puncture until 180 min following it.
7 secondary outcomes
The onset time of significant shivering
Time frame: started from 15 minutes after lumbar injection until 180 minutes following lumbar injection and postoperative
Incidence of hypothermia
Time frame: started from 15 minutes after lumbar injection until 180 minutes after lumbar injection and postoperative.
The shivering score
Time frame: will be assessed at 15 minutes intervals during the operation and in the recovery room started from 15 minutes after the lumbar puncture until 180 minutes after the lumbar puncture and postoperative.
Incidence of patients given pethidine
Time frame: started from 15 minutes after the lumbar puncture until 180 minutes after the lumbar puncture and postoperativde.
Correlation between the incidence of shivering score ≥ 3 and hypothermia.
Time frame: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively
The incidence of adverse effects
Time frame: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively
Correlation between the incidences of postoperative nausea, vomiting, and shivering
Time frame: started 15 minutes after lumbar puncture until 180 minutes after lumbar puncture and postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2025.
Related trials for Post-Spinal Shivering
Not yet recruitingPhase 4
Two Doses of IV Magnesium Sulfate for Prevention of Post-Spinal Shivering
Post Spinal Anesthesia Shivering
Not yet recruitingPhase 4
Optimizing the Paracetamol Dose for Prevention of Post-Spinal Shivering in Lower Limb Orthopedic Surgeries
Shivering, Postoperative Shivering
Not yet recruitingPhase 4
Effect of Preoperative Intranasal Dexmedetomidine on Incidence of Intraoperative Shivering in Patients Undergoing Cesarean Section Under Spinal Anesthesia
Shivering, Hypothermia
Not yet recruitingPhase 4
Intravenous Paracetamol Versus Magnesium Sulfate for Control of Shivering Following Spinal Anesthesia in Cesarean Section
Shivering, Post-Spinal Shivering
Not yet recruitingPhase 4
Efficacy of Intravenous Midazolam-Ketamine Combination Versus Placebo for Prevention of Post-Spinal Shivering in Elective Cesarean Section
Shivering, Post-Spinal Shivering
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Oral ondansetron strips in people with Post-Spinal Shivering, run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence of shivering. (time frame: starting from 15 minutes after lumber puncture until 180 minutes following it and postoperative.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2025.